Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

C. difficile in 2011 is less severe with better outcomes than the infection in 2008

The latest issue of the American Journal of Gastroenterology compares the demographics, medication exposure, treatment patterns, and outcomes of patients with C. difficile in 2 different time periods.

News image

Over the past decade, the epidemiology of Clostridium difficile infection (CDI) has shown a remarkable increase in incidence with an associated increase in severity.

Dr Paul Feuerstadt and colleagues from Connecticut, USA compared the demographics, medication exposure, evaluation, treatment patterns, and outcomes of patients with CDI in 2 different time periods, including 20062008 and 20092011.

The researchers hypothesized that mortality is decreasing with increasing appropriateness of medical management.

The team retrospectively identified consecutive patients admitted to Montefiore Medical Center between 1/1/2006 and 12/31/2011 with symptomatic diarrhea, and a positive C. difficile toxin assay.

Factors associated with 30-day mortality include age, white blood cells, and albumin level
American Journal of Gastroenterology

The cohort was subdivided into those diagnosed in 20062008, and 20092011.

The research team obtained key parameters at the time of diagnosis including demographics, medication exposure, medical comorbidities, laboratory data, CDI evaluation, and various outcome measures.

The team created a subcohort for each time frame of patients diagnosed with severe CDI defined by white blood cell count >15,000 cells/μl, and albumin <3.0 g/dl and made the same comparisons as for the overall cohort.

The resesarch team identified 4 cohorts including CDI 200608, CDI 200911, severe CDI 200608, and severe CDI 200911.
 
CDI 0911 patients were older and had higher Charlson comorbidity scores than did those in the CDI 0608 cohort.

The team observed no significant demographic differences in the severe cohort.

For both the overall and severe cohorts, there was more macrolide exposure before diagnosis with CDI, and lower rates of quinolone exposure in the more recent era.

The researchers found that the disease process also appeared less severe in the CDI 200911 cohort with lower peak white blood cells during admission and at diagnosis.

Treatment patterns appeared more aggressive during the more recent time frame, with shorter durations of oral metronidazole, longer durations of IV metronidazole, more frequent use of vancomycin as the sole therapy, more frequent switching from metronidazole to vancomycin, and less frequent exposure to any metronidazole throughout treatment in the overall cohort.

The researchers found that the 30-day mortality decreased significantly in both the overall, and the severe cohorts from CDI 0608 to CDI 0911, with mortality decreasing significantly in the 8th and 9th decades of life in the overall cohort and in the 8th, 9th, and 10th decades in the severe cohort.

Dr Feuerstadt's team concludes, "In an urban United States population, CDI 200911 showed changes in medication exposures, less severe disease, and more aggressive management with better outcomes and decreased mortality compared with CDI 0608."

"The most important factors associated with 30-day mortality in both an overall and severe CDI population include age, white blood cells, and albumin level at the time of diagnosis."

Am J Gastroenterol 2014; 109:12651276
18 August 2014

Go to top of page Email this page Email this page to a colleague

 29 January 2015

Advanced search
 29 January 2015 
Pyloric compliance in gastroparesis
 29 January 2015 
Gastric cancer in peptic ulcer disease
 29 January 2015 
Genetics and risk of Barrett's
 28 January 2015 
Metabolic syndrome in celiac disease
 28 January 2015 
Remission in Crohn's disease
 28 January 2015 
Surgery and quality of life in rectal cancer
 27 January 2015 
Outcomes for liver transplantation
 27 January 2015 
Psychological distress and fecal composition in IBS
 27 January 2015 
Risk of upper GI cancers in GERD
 26 January 2015 
Breath analysis for IBD
 26 January 2015 
Fecal microbiota transplantation
 26 January 2015 
Antidepressants and GERD
 23 January 2015 
Liver transplant outcomes
 23 January 2015 
Breath analysis in IBD
 23 January 2015 
Fecal microbiota transplantation
 22 January 2015 
NASH and lipid improvements
 22 January 2015 
NAFLD and NASH with psoriasis
 22 January 2015 
Predicting outcomes in HCV-related advanced liver disease
 21 January 2015 
Colon capsule versus CT colonography
 21 January 2015 
Barrett's esophagus screening in the community
 21 January 2015 
Portal vein obstruction
 20 January 2015 
Modulating mucosal damage in Crohn's
 20 January 2015 
Novel techniques for Barrett's screening
 20 January 2015 
Food intolerance
 19 January 2015 
Treatment of fecal incontinence
 19 January 2015 
Hepatic cyst infection
 19 January 2015 
Risk of IBS among relatives
 16 January 2015 
Colorectal cancer screening uptake
 16 January 2015 
NAFLD and NASH in patients with psoriasis
 16 January 2015 
Fecal incontinence
 15 January 2015 
Coffee intake and liver disease
 15 January 2015 
NAFLD in primary care practice
 15 January 2015 
Management of univestigated dyspepsia
 14 January 2015 
Missed colorectal cancers after colonoscopy with polypectomy
 14 January 2015 
Inflixmab response in Crohn's
 14 January 2015 
Statins and liver injury in chronic liver disease
 13 January 2015 
Cytomegalovirus in IBD
 13 January 2015 
Helicobacter-negative gastritis
 13 January 2015 
Hep B vaccine in IBD
 12 January 2015 
Survival in Hep B virus-related hepatocellular carcinoma
 12 January 2015 
Relapse of Crohn's disease after surgery
 12 January 2015 
Late liver metastases of colorectal cancer
 09 January 2015 
Fecal microbiota transplantation for refractory Crohn's
 09 January 2015 
Hypercoagulability after liver resection
 09 January 2015 
Naps and gastroesophageal reflux vs nocturnal sleep
 08 January 2015 
Post-infectious functional dyspepsia
 08 January 2015 
Diagnosis of liver iron overload
 08 January 2015 
Digestive tract damage in Crohn's disease
 07 January 2015 
Early-onset colorectal cancer
 07 January 2015 
SSRIs for noncardiac chest pain
 07 January 2015 
SSRIs and upper GI bleeds
 06 January 2015 
Detection of inflammation in Crohn's
 06 January 2015 
Leptin and early-onset extreme obesity
 06 January 2015 
Goals of IBD treatment
 19 December 2014 
Thiopurine treatment and colectomy in ulcerative colitis
 19 December 2014 
Idiopathic inflammatory demyelinating disease in IBD
 19 December 2014 
Colorectal cancer risk for first-degree relatives
 18 December 2014 
Vitamin D and sustained virologic response in HCV
 18 December 2014 
Factor for treatment in IBS
 18 December 2014 
Assessment of Crohn's disease activity

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us